CliffBio
small molecule

PROTONIX IV

PANTOPRAZOLE SODIUM

Loss of exclusivityAugust 2027FDA regulatory exclusivity expiry
CompanyWyeth →See this company's full patent-cliff portfolio

Drug detail

Brand namePROTONIX IV
Active ingredientPANTOPRAZOLE SODIUM
StrengthEQ 40MG BASE/VIAL
Dosage formINJECTABLE
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2001
Marketing statusRX

Regulatory exclusivity

CodeExpires
NPPAugust 2027

More from Wyeth

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.